SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Allen Scroggins who wrote (505)11/19/1997 11:21:00 PM
From: john b  Read Replies (1) of 998
 
Allen,

Are we the only people who think Cephalon is a very good bargain at this price? I have been watching CEPH for several years. It was $7- 8 a share before the results from early clinical trials for myotrophin were disclosed, and quickly doubled, then tripled on the positive results.

I think investors are losing sight of the fact that this company has several other products in the pipeline, maybe not as BIG as myotrophin, but still with great potential. And, the company still has a good cash balance to get them through a couple of more years of research on its various projects.

Any opinions out there?

john b
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News